94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Daniel Morales-Cano1,2,3,4,5†
Jose Luis Izquierdo-García2,6,7†
Bianca Barreira1,2,3
Sergio Esquivel-Ruiz1,2,3Maria Callejo1,2,3
Rachele Pandolfi1,2,3
Palmira Villa-Valverde2,8Ignacio Rodríguez2,6
Angel Cogolludo1,2,3
Jesus Ruiz-Cabello2,6,9
Francisco Perez-Vizcaino1,2,3‡
Laura Moreno1,2,3*‡- 1Department of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
- 2Ciber Enfermedades Respiratorias (Ciberes), Madrid, Spain
- 3Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
- 4Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
- 5Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
- 6Department of Chemistry in Pharmaceutical Sciences, School of Pharmacy, Universidad Complutense de Madrid, Madrid, Spain
- 7Instituto Pluridisciplinar, Universidad Complutense de Madrid, Madrid, Spain
- 8ICTS Bioimagen Complutense, Universidad Complutense de Madrid, Madrid, Spain
- 9Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia San Sebastián, Spain
by Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F and Moreno L (2023). Front. Pharmacol. 14:1021535. doi: 10.3389/fphar.2023.1021535
In the published article, there was an error in Figure 2 as published. There was a mistake in the identification of two of the panels (B and C) which were described respectively as “(B) systolic PAP (sPAP) and (C) diastolic PAP (dPAP).” The corrected Figure 2, and it is caption, appear below.
FIGURE 2
FIGURE 2. Treatment with riociguat alone or combined with 5-z-7oxozeaenol attenuates pulmonary hypertension in the Sugen 5426/hypoxia (SuHyp) rat model. (A) Mean pulmonary arterial pressure (mPAP), (B) diastolic PAP (dPAP) and (C) systolic PAP (sPAP) in control (NMX-Vh) and SuHyp rats treated with vehicle, 5Z-7-oxozeaenol (SuHyp-OXO; 3 mg·kg−1·day−1), riociguat (SuHyp-RIO; 3 mg·kg−1·day−1) or both drugs combined (SuHyp-OXO-RIO). (D) Representative PAP recordings in each treatment group. (E) Right systolic and (F) end-diastolic ventricular pressure (RVSP and RVEDP). (G) Fulton index (ratio between RV and left ventricle plus septum weight) and (H) right ventricular weight relative to total body weight in the different treatment groups. Each bar shows the mean +SEM (n = 6–10 animals in each group). *p < 0.05 versus NMX-Vh and #p < 0,05 versus SuHyp vehicle (One-way ANOVA followed by Bonferroni´s post hoc test).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: pulmonary hypertension, antiproliferative, metabolomics, combination therapy, right ventricle
Citation: Morales-Cano D, Izquierdo-García JL, Barreira B, Esquivel-Ruiz S, Callejo M, Pandolfi R, Villa-Valverde P, Rodríguez I, Cogolludo A, Ruiz-Cabello J, Perez-Vizcaino F and Moreno L (2023) Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model. Front. Pharmacol. 14:1228923. doi: 10.3389/fphar.2023.1228923
Received: 25 May 2023; Accepted: 30 May 2023;
Published: 12 June 2023.
Edited and reviewed by:
Alessia Vignoli, University of Florence, ItalyCopyright © 2023 Morales-Cano, Izquierdo-García, Barreira, Esquivel-Ruiz, Callejo, Pandolfi, Villa-Valverde, Rodríguez, Cogolludo, Ruiz-Cabello, Perez-Vizcaino and Moreno. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Laura Moreno, bG1vcmVub2dAbWVkLnVjbS5lcw==
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship